FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q83323101> ?p ?o ?g. }

• Q83323101 description "2011 nî lūn-bûn" @default.
• Q83323101 description "2011 թվականի հունվարի 11-ին հրատարակված գիտական հոդված" @default.
• Q83323101 description "2011年の論文" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年学术文章" @default.
• Q83323101 description "2011年學術文章" @default.
• Q83323101 description "2011年學術文章" @default.
• Q83323101 description "2011年學術文章" @default.
• Q83323101 description "2011年學術文章" @default.
• Q83323101 description "2011年學術文章" @default.
• Q83323101 description "2011년 논문" @default.
• Q83323101 description "article científic" @default.
• Q83323101 description "article scientific" @default.
• Q83323101 description "article scientifique" @default.
• Q83323101 description "articol științific" @default.
• Q83323101 description "articolo scientifico" @default.
• Q83323101 description "artigo científico" @default.
• Q83323101 description "artigo científico" @default.
• Q83323101 description "artigo científico" @default.
• Q83323101 description "artikel ilmiah" @default.
• Q83323101 description "artikull shkencor" @default.
• Q83323101 description "artikulong pang-agham" @default.
• Q83323101 description "artykuł naukowy" @default.
• Q83323101 description "artículo científico publicado en 2011" @default.
• Q83323101 description "artículu científicu" @default.
• Q83323101 description "bilimsel makale" @default.
• Q83323101 description "bài báo khoa học" @default.
• Q83323101 description "naučni članak" @default.
• Q83323101 description "scienca artikolo" @default.
• Q83323101 description "scientific article published on 11 January 2011" @default.
• Q83323101 description "scientific article published on 11 January 2011" @default.
• Q83323101 description "scientific article published on 11 January 2011" @default.
• Q83323101 description "teaduslik artikkel" @default.
• Q83323101 description "tieteellinen artikkeli" @default.
• Q83323101 description "tudományos cikk" @default.
• Q83323101 description "vedecký článok" @default.
• Q83323101 description "vetenskaplig artikel" @default.
• Q83323101 description "videnskabelig artikel udgivet 11. januar 2011" @default.
• Q83323101 description "vitenskapelig artikkel" @default.
• Q83323101 description "vitskapeleg artikkel" @default.
• Q83323101 description "vědecký článek" @default.
• Q83323101 description "wetenschappelijk artikel" @default.
• Q83323101 description "wissenschaftlicher Artikel" @default.
• Q83323101 description "επιστημονικό άρθρο" @default.
• Q83323101 description "мақолаи илмӣ" @default.
• Q83323101 description "наукова стаття, опублікована в січні 2011" @default.
• Q83323101 description "научна статия" @default.
• Q83323101 description "научная статья" @default.
• Q83323101 description "научни чланак" @default.
• Q83323101 description "научни чланак" @default.
• Q83323101 description "מאמר מדעי" @default.
• Q83323101 description "مقالة علمية نشرت في 11 يناير 2011" @default.
• Q83323101 description "১১ জানুয়ারি ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q83323101 description "บทความทางวิทยาศาสตร์" @default.
• Q83323101 description "სამეცნიერო სტატია" @default.
• Q83323101 name "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 name "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 type Item @default.
• Q83323101 label "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 label "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 prefLabel "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 prefLabel "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 P1433 Q83323101-524C5E6B-67F0-4BA4-8702-754823F79C7C @default.
• Q83323101 P1476 Q83323101-0BBD6699-5B65-40BA-9D9E-2C65DA649B4B @default.
• Q83323101 P2093 Q83323101-0FFB23BF-14C2-445E-97C1-BB3413198A7B @default.
• Q83323101 P2093 Q83323101-236EB0A9-6FA8-4908-AC16-2202F399F2A0 @default.
• Q83323101 P2093 Q83323101-2C150F31-5D27-4E95-AEBF-F0DB347BD32E @default.
• Q83323101 P2093 Q83323101-306B71C6-1D6E-43C6-A3B2-19AB3BCE3357 @default.
• Q83323101 P2093 Q83323101-47A38EB8-ADA2-483E-A661-EFDCD5CC86F4 @default.
• Q83323101 P2093 Q83323101-49F58894-2F20-46F4-9500-D5A677D588CF @default.
• Q83323101 P2093 Q83323101-5729929F-3B3F-4716-B67D-A6CF295E70C9 @default.
• Q83323101 P2093 Q83323101-5AAEDF3A-CC8D-4CF6-8B33-4DA2945F5833 @default.
• Q83323101 P2093 Q83323101-5CFF3903-CD76-47F9-9E74-BA42E529E767 @default.
• Q83323101 P2093 Q83323101-74CF3553-901A-4461-87F3-9A5075DD8936 @default.
• Q83323101 P2093 Q83323101-8C2CEBC8-EE0F-4CA0-BBE2-A45A32094BE3 @default.
• Q83323101 P2093 Q83323101-99999429-2210-4FB0-AB54-F3B5D396FCA1 @default.
• Q83323101 P2093 Q83323101-B53AD514-96BA-44DF-A735-694AB1A1DB6C @default.
• Q83323101 P2093 Q83323101-BC4B8E06-0A0F-4A79-A8BF-07C1EB658BAD @default.
• Q83323101 P2093 Q83323101-C065F42A-B6D9-45E3-95AB-57D769C5FB92 @default.
• Q83323101 P304 Q83323101-109E67C8-F3AA-49D2-A888-1172E8595B46 @default.
• Q83323101 P31 Q83323101-DB447922-1F4D-4A16-9178-C9E473D0FE1E @default.
• Q83323101 P356 Q83323101-F4894689-118A-4AAD-A343-2FF7C552673A @default.
• Q83323101 P433 Q83323101-AC056D4B-C7C5-49E3-9243-DC25E288DE14 @default.
• Q83323101 P478 Q83323101-56BE1518-1AEA-47A7-90DA-55689B93BA08 @default.
• Q83323101 P577 Q83323101-AED33437-37F3-4088-8A70-0EFEF99DE6C0 @default.
• Q83323101 P698 Q83323101-008FD569-D05C-4F95-9AFE-DAC2AF548375 @default.
• Q83323101 P921 Q83323101-AE439406-6AD3-411B-B9A5-CA92DE956AFB @default.
• Q83323101 P356 J.RMR.2010.06.027 @default.
• Q83323101 P698 21277474 @default.
• Q83323101 P1433 Q15708750 @default.
• Q83323101 P1476 "[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]" @default.
• Q83323101 P2093 "A Lavole" @default.
• Q83323101 P2093 "B Milleron" @default.
• Q83323101 P2093 "C Hennequin" @default.
• Q83323101 P2093 "C Le Pechoux" @default.
• Q83323101 P2093 "F Morin" @default.

• next